Molbio Diagnostics Limited Initial Public Offering To Open on Monday, August 10, 2026 price band fixed at ₹768-807 Per Equity Share

 MUMBAI: Temasek and Motilal Oswal Group-backed Molbio Diagnostics has fixed the price band for its ₹930.7-crore initial public offering (IPO) at ₹768-807 per share. The public issue will open for subscription on August 10 and close on August 12, while the anchor investor book will open on August 7.

Investors can bid for a minimum of 18 equity shares and in multiples thereafter. At the upper end of the price band, the IPO is valued at ₹930.7 crore. The issue comprises a fresh issue of shares worth ₹200 crore and an offer for sale (OFS) of 91.66 lakh shares by existing shareholders.

The IPO will open alongside the ₹3,067-crore Dhoot Transmission public issue, making it one of two mainboard IPOs scheduled to launch on August 10. The OFS includes shares being sold by promoters Exxora Trading and Dr Chandrasekhar Bhaskaran Nair, investor India Business Excellence Fund, and seven other shareholders.

Following the issue, the promoters’ stake will dilute from the current 46.65%, while the remaining 53.35% is held by investors, including Temasek Holdings-backed V Sciences Investments and Motilal Oswal Group’s India Business Excellence Fund.

Goa-based Molbio Diagnostics develops point-of-care (POC) diagnostic solutions. Its flagship Truenat platform, patented in more than 100 countries, enables rapid molecular testing for diseases such as tuberculosis (TB), COVID-19, Hepatitis B and C, Human Immunodeficiency Virus (HIV), and Human Papillomavirus (HPV).

The PCR-based platform is designed to deliver decentralised diagnostic results within an hour, particularly in resource-constrained settings.

The company plans to utilise ₹105.5 crore from the fresh issue proceeds to establish a research and development facility and a Centre of Excellence through its wholly owned subsidiary, Bigtec, along with office infrastructure as told to our newsman Sachin Murdeshwar. Another ₹72.2 crore will be used to purchase plant, machinery and equipment for its manufacturing facilities in Goa and Visakhapatnam, while the remaining proceeds will be used for general corporate purposes.

The Molbio Diagnostics Management present at the IPO were Sriram Natarajan, Executive Director and Chief Executive Office; Dr. Chandrasekhar Bhaskaran Nair, Executive Director and Chief Technology Officer

Manan Bimal Khokhani, President Finance and Accounts and Chief Financial Officer

Shiva Sriram, President, Business Development and Indraneil Borkakoty, President – Corporate Strategy, Mergers and Acquisitions and Investor Relations

Molbio Diagnostics reported strong financial performance in FY26, with net profit rising 14.8% to ₹166.6 crore, while revenue increased 41.7% to ₹1,445.7 crore.Kotak Mahindra Capital Company, IIFL Capital Services and Jefferies India are the book-running lead managers to the issue.

The basis of allotment is expected to be finalised on August 13, with the company’s shares likely to list on the stock exchanges on August 17.